Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography)

1. Why Biosimilars superior to Biologics?

2. 114 Pages Report 112 Pages Report 145 Pages Report 140 Pages Report 86 Pages Report 184 Pages Report 108 Pages Report 105 Pages Report 95 Pages Report Published Date : 15 April 2014 Published Date : 21 April 2014 Published Date: 1 July 2014 Published Date : 25 June 2014 Published Date : 07 April 2014 Published Date : 30 June 2014 Published Date: 08 April 2014 Published Date: 18 March 2014

3. Introduction Table of Content Introduction Executive Summary Global 3D Technology Market Overview Global 3D Technology Market by Products Global 3D Technology Market by Applications Global 3D Technology Market by Geography Company Profiles Key Audiences Scope of the Report Key Benefits

4. Table of Contents INTRODUCTION EXECUTIVE SUMMARY MARKET OVERVIEW GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS MARKET BY TECHNOLOGY GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY PRODUCT TYPE GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY APPLICATIONS GLOBAL BIOSIMILARS / FOLLOW-ON-BIOLOGICS MARKET BY SERVICES GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY GEOGRAPHIES KEY PRODUCTS AND RECENT ACTIVITIES BY GEOGRAPHY 10 . COMPANY PROFILES

5. Description Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020. Regulations for biosimilars plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the biosimilars market. Regulations in the European union are considered benchmark around the world, as the guidelines proposed are most stringent for validation and commercialization of biosimilars. High profitability is the attractive aspect that is enticing companies to invest in the biosimilars industry. 

6. KEY BENEFITS • The study is segmented in a strategic divisions to gain deeper insights into the market dynamics and understand the competitive environment of the overall market  • Financial market forecast is provided for the next eight years by considering 2013 as the base year • Comprehensive and quantitative data about changing market trends, intensifying competition and opportunities in biosimilars market are provided to make better business decisions • Porter’s Five Forces model and SWOT analysis of the overall market is provided to help stakeholders gain strategic insights of the market • Deep dive analysis of key market players and strategies adopted by them are expounded to provide valuable information on the top contenders in the market • Identification of key investment pockets for the biosimilars market is strategically dealt to assist the stakeholders 

7. Global Biosimilars Market Overview Diverse approach of global regulators towards biosimilars Market Definition and Scope Safety issues of  biosimilar drugs Value chain analysis Global Biosimilars Market Overview Porters five force analysis Key Findings Emerging economies a hotspot for biosimilars market Regulation & Reimbursement scenario

8. Market Dynamics Market Dynamics Your feedback is important to us What would you like to know more about this Study ? • Global Industry Analysis • Market Size • Market Share • Market Trends • Opportunities and Forecast Market Restraints Key Market Drivers High prevalence of chronic diseases among population Growing pressure to reduce healthcare expenditure Various blockbusters going off patent Lower cost biosimilars drugs than original biologics High initial investment in research and development Medical Efficacy and Patient Safety Please inform us on : http://www.alliedmarketresearch.com/contact-us Economic and scientific obstacles   High cost of Production

9. GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET By APPLICATIONS

10. GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS  MARKET BY TECHNOLOGIES Monoclonal Antibodies (MAb) Technology Recombinant DNA Technology Chromatography Market By Technologies Nuclear magnetic resonance (NMR) technology Electrophoresis MASS SPECTROMETRY Western Blotting Bioassay

11. GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS  MARKET By , GEOGRAPHY

12. Top Market Players of Biosimilars/Follo-On-Biologics Market • Novartis (Sandoz) • Synthon Pharmaceuticals, Inc. • Teva Pharmaceutical Industries Ltd. • LG Life Sciences • Celltrion • Biocon • Hospira • Merck Serono (Merck Group) • Biogenidec Inc. • Genentech (Roche Group)

13. Your feedback is important to us What would you like to know more about this Study ? • Global Industry Analysis • Market Size • Market Share • Market Trends • Opportunities and Forecast Please inform us on : http://www.alliedmarketresearch.com/contact-us

14. To View the Complete Report Visit - http://www.alliedmarketresearch.com/ biosimilars-market